Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

PGEN
Precigen, Inc. Common Stock
stock NASDAQ

At Close
Aug 15, 2025 3:59:51 PM EDT
2.94USD+58.919%(+1.09)173,718,338
0.00Bid   0.00Ask   0.00Spread
Pre-market
Aug 15, 2025 9:29:58 AM EDT
2.61USD+41.081%(+0.76)2,012,492
After-hours
Aug 15, 2025 4:59:44 PM EDT
2.80USD-4.762%(-0.14)308,803
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 12, 2022
04:32PM EST  Precigen Announced Enrollment Completion For Dose Level 3 Of Lymphodepletion Cohort, Provides Pipeline Update At J.P. Morgan Health Conference   Benzinga
04:30PM EST  Precigen Provides Pipeline and Corporate Updates at the 40th Annual J.P. Morgan   PR Newswire
Jan 5, 2022
04:05PM EST  Precigen to Present at the 40th Annual J.P. Morgan Healthcare Conference   PR Newswire
Dec 14, 2021
08:08AM EST  Precigen Reveals Early Data From CAR-T Candidate In Blood Cancer Patients   Benzinga
Dec 13, 2021
05:06PM EST  Precigen Reports Interim Phase 1 Data For PRGN-3006 Ultra CAR-T In Relapsed, Refractory Acute Myeloid Leukemia: 'single administration of UltraCAR-T cells following overnight manufacturing demonstrated robust expansion, persistence in blood and bone marro   Benzinga
05:05PM EST  Precigen Announces Positive Interim Phase 1 Data for PRGN-3006 UltraCAR-T(r) in   PR Newswire
Nov 10, 2021
04:06PM EST  Precigen to Present at the Stifel 2021 Virtual Healthcare Conference   PR Newswire
Nov 4, 2021
09:33AM EDT  Precigen Achieves Significant Clinical Progress For UltraCAR-T And AdenoVerse Therapies   Benzinga
09:16AM EDT  Precigen Achieves Significant Clinical Progress for UltraCAR-T(r) and   PR Newswire
Oct 27, 2021
04:39PM EDT  Precigen to Host R&D Update Virtual Event on November 4th to Share Clinical   PR Newswire
Oct 26, 2021
08:14AM EDT  Precigen Announces Clearance Of IND To Initiate Phase 1/1b Study For PRGN-3007 UltraCAR-T In Advanced ROR1+ Hematological And Solid Tumors   Benzinga
08:07AM EDT  Precigen Clears IND To Initiate Phase 1/1b Study For PRGN-3007 UltraCAR-T In ROR1+ Hematological And Solid Tumors   RTTNews
08:06AM EDT  Precigen Announces Clearance of IND to Initiate Phase 1/1b Study for PRGN-3007   PR Newswire
Oct 18, 2021
02:10PM EDT  Preview: Procter & Gamble's Earnings   Benzinga
Oct 12, 2021
08:08AM EDT  Precigen Appoints Harry Thomasian As CFO, Effective October 18   RTTNews
08:08AM EDT  Precigen Appoints Harry Thomasian Jr. As Chief Financial Officer   Benzinga
Oct 1, 2021
08:31AM EDT  Precigen ActoBio, a wholly-owned subsidiary of Precigen Inc. (PGEN), announced additional positive interim data from the ongoing Phase 1b/2a clinical study investigating AG019 ActoBiotics for the treatment of recent-onset type 1 diabetes or T1D.   RTTNews
08:15AM EDT  Precigen ActoBio Announces Additional Interim Data From Phase 1b/2a Study Of AG019 ActoBiotics   Benzinga
08:13AM EDT  Precigen Reports Positive Data From Phase 1b/2a Study Of AG019 ActoBiotics For Recent-onset Type 1 Diabetes Treatment   RTTNews
08:06AM EDT  Study of AG019 ActoBiotics(tm), A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes   PR Newswire
07:56AM EDT  The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO   Benzinga
Sep 17, 2021
10:39AM EDT  Precigen Earnings Perspective: Return On Capital Employed   Benzinga
Sep 1, 2021
08:05AM EDT  Precigen to Present at the 2021 Wells Fargo Virtual Healthcare Conference and   PR Newswire
Aug 9, 2021
04:22PM EDT  Precigen: Q2 Earnings Insights   Benzinga
04:22PM EDT  Precigen Q2 EPS $(0.10) Beats $(0.12) Estimate, Sales $33.58M Beat $21.07M Estimate   Benzinga
04:02PM EDT  Precigen Reports Second Quarter and First Half 2021 Financial Results   PR Newswire
11:07AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
04:11AM EDT  Earnings Scheduled For August 9, 2021   Benzinga
Aug 8, 2021
10:11AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
Aug 2, 2021
04:06PM EDT  Precigen to Announce Second Quarter and First Half 2021 Financial Results on   PR Newswire
Jun 25, 2021
10:44AM EDT  Precigen Insights: Return On Capital Employed   Benzinga
Jun 15, 2021
11:26AM EDT  Precigen Granted U.S. Patent Titled 'Expression of novel cell tags'   Benzinga
Jun 11, 2021
10:39AM EDT  Shares of Precigen, Inc. (PGEN) are climbing more than 12% Friday morning.   RTTNews
08:05AM EDT  The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts   Benzinga
06:59AM EDT  Precigen Stock Surges On Positive AG019 Data for Chronic Treatment Of Type 1 Diabetes   Benzinga
Jun 10, 2021
05:05PM EDT  AG019 ActoBiotics(tm), A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes   PR Newswire
04:06PM EDT  Precigen to Present at the JMP Securities Life Sciences Conference   PR Newswire
08:13AM EDT  The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal   Benzinga
Jun 9, 2021
10:44AM EDT  Precigen: Return On Capital Employed Insights   Benzinga
May 28, 2021
06:21AM EDT  Precigen 8-K Shows Co. Names James Lambert Interim Principal Accounting Officer While Co. Continues Search For New Permanent CFO Replacement   Benzinga
May 10, 2021
05:05PM EDT  Precigen Q1 Sales $24.51M Down From $29.84M YoY   Benzinga
04:30PM EDT  Precigen Reports First Quarter 2021 Financial Results   PR Newswire
Apr 7, 2021
12:21AM EDT  Exclusive: Precigen's CEO Breaks Down Biotech's Oncology Platforms, Technology, Differentiators   Benzinga
Mar 30, 2021
04:12PM EDT  Precigen Reports CFO, Rick Sterling, To Step Down; Co. Commenced Search For Successor   Benzinga
04:05PM EDT  Precigen Announces Departure of Chief Financial Officer   PR Newswire
Mar 23, 2021
08:12AM EDT  Precigen Announces First Patient Dosed For PRGN-2012 AdenoVerse Immunotherapy In Patients With Recurrent Respiratory Papillomatosis   Benzinga
08:07AM EDT  Precigen Doses First Patient Dosed For PRGN-2012 AdenoVerse Immunotherapy In Recurrent Respiratory Papillomatosis   RTTNews
08:06AM EDT  Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)   PR Newswire
Mar 18, 2021
09:51AM EDT  Precigen shares were trading higher after the company announced it received FDA Orphan Drug Designation for its adenoviral vector expressing HPV 6 and HPV 11 antigens for the treatment of recurrent respiratory papillomatosis.   Benzinga
09:09AM EDT  Looking Into Precigen's Return On Capital Employed   Benzinga
08:49AM EDT  Precigen Confirms Yesterday Report Co Received FDA Orphan Drug Designation For PRGN-2012 AdenoVerse Immunotherapy In Patients With Recurrent Respiratory Papillomatosis   Benzinga
08:38AM EDT  Precigen Gets FDA ODD For PRGN-2012 AdenoVerse Immunotherapy In Patients With Recurrent Respiratory Papillomatosis   RTTNews
08:31AM EDT  Precigen Receives FDA Orphan Drug Designation for PRGN-2012 AdenoVerse(tm)   PR Newswire
Mar 17, 2021
07:07PM EDT  Precigen Received FDA Orphan Drug Designation for Adenoviral Vector Expressing HPV 6 and HPV 11 Antigens for Treatment of Recurrent Respiratory Papillomatosis   Benzinga
Mar 1, 2021
04:54PM EST  Recap: Precigen Q4 Earnings   Benzinga
04:09PM EST  Precigen Q4 EPS $(0.22) Misses $(0.17) Estimate, Sales $19.30M Beat $16.96M Estimate   Benzinga
04:06PM EST  Precigen Reports Fourth Quarter and Full Year 2020 Financial Results   PR Newswire
03:51AM EST  Earnings Scheduled For March 1, 2021   Benzinga
Feb 27, 2021
09:04PM EST  The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings   Benzinga
Feb 25, 2021
10:03AM EST  Benzinga's Top Ratings Upgrades, Downgrades For February 25, 2021   Benzinga
08:10AM EST  Stifel Initiates Coverage On Precigen with Buy Rating, Announces Price Target of $13   Benzinga
Feb 22, 2021
04:06PM EST  Precigen to Announce Fourth Quarter and Full Year 2020 Financial Results on   PR Newswire
10:03AM EST  Benzinga's Top Ratings Upgrades, Downgrades For February 22, 2021   Benzinga
08:09AM EST  Wells Fargo Initiates Coverage On Precigen with Overweight Rating, Announces Price Target of $14   Benzinga
Feb 4, 2021
04:06PM EST  Precigen to Participate in Guggenheim Healthcare Talks Oncology Day   PR Newswire
Jan 26, 2021
04:05PM EST  Precigen Announces Closing of Public Offering of Common Stock and Full Exercise   PR Newswire
Jan 22, 2021
10:14AM EST  Shares of Precigen, Inc. (PGEN) slipped 7% on Friday morning after the company said it will raise $112.5 million from a public offering of 15 million common shares.   RTTNews
08:08AM EST  Precigen Prices 15M Share Offering At $7.50/Share   Benzinga
08:07AM EST  Precigen Prices Public Offering Of 15 Mln Shares At $7.50 Per Share   RTTNews
08:05AM EST  Precigen Announces Pricing of $112.5 Million Public Offering of Common Stock   PR Newswire
07:22AM EST  The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa   Benzinga
Jan 21, 2021
04:02PM EST  Precigen Announces A Common Stock Offering   Benzinga
04:01PM EST  Precigen Announces Proposed Public Offering of Common Stock   PR Newswire
Jan 13, 2021
04:06PM EST  Precigen Provides Pipeline Updates at the 39th Annual J.P. Morgan Healthcare   PR Newswire
Jan 6, 2021
08:05AM EST  Precigen to Present at the 39th Annual J.P. Morgan Healthcare Conference   PR Newswire
Jan 5, 2021
08:39AM EST  The Daily Biotech Pulse: Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data   Benzinga
08:12AM EST  Precigen Reports Clearance Of IND To Initiate Phase I Study Of PRGN-2012 AdenoVerse Immunotherapy In Patients With RRP   RTTNews
08:07AM EST  Precigen Announces Clearance Of IND To Initiate Phase I Study Of PRGN-2012 AdenoVerse Immunotherapy In Patients With Recurrent Respiratory Papillomatosis   Benzinga
08:05AM EST  AdenoVerse(tm) Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)   PR Newswire
Dec 29, 2020
08:09AM EST  The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica   Benzinga
Dec 23, 2020
08:31AM EST  The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut   Benzinga
Dec 22, 2020
07:45AM EST  The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes   Benzinga
Dec 16, 2020
06:08AM EST  HC Wainwright & Co. Maintains Buy on Precigen, Raises Price Target to $10   Benzinga
Dec 15, 2020
07:38PM EST  Precigen Provides Latest Clinical Developments at Virtual R&D Update Event   PR Newswire
07:52AM EST  The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding   Benzinga
Dec 8, 2020
04:06PM EST  Precigen to Host R&D Update Virtual Event on December 15th to Share Latest   PR Newswire
Dec 7, 2020
10:12AM EST  Precigen Presents New Data Supporting Safety, Clinical Activity, Expansion, Persistence Of PRGN-3006 UltraCAR-T At ASH   Benzinga
10:08AM EST  and Persistence of PRGN-3006 UltraCAR-T(r) at the 62nd ASH Annual Meeting and Exposition   PR Newswire
Dec 6, 2020
08:41AM EST  Week Ahead In Biotech: FDA To Decide On Emergency Use Of Pfizer's COVID Vaccine, Hematology Conference Presentations Pick Up Pace   Benzinga
Dec 4, 2020
11:00AM EST  PGEN Final Deadline: Bronstein, Gewirtz & Grossman, LLC Notifies Precigen, Inc. f/k/a Intrexon Corporation Shareholders of Class Action and Lead Plaintiff Deadline: December 4, 2020   Business Wire
08:04AM EST  The Daily Biotech Pulse: BioCryst's Heredity Angioedema Treatment Clears FDA, Sutro Biopharma Readout, 2 IPOs   Benzinga
08:00AM EST  Investors with losses are encouraged to contact the firm before December 4, 2020; click here to submit trade information   GlobeNewswire Inc
07:43AM EST  The Daily Biotech Pulse: BioCryst's Heredity Angioedema Treatment Clears FDA, Sutro Biopharma Readout, 2 IPOs   Benzinga
Dec 3, 2020
04:54PM EST  Hagens Berman urges Precigen, Inc. (NASDAQ PGEN) (f/k/a Intrexon) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have sufficient losses to move for lead plaintiff.   GlobeNewswire Inc
01:20PM EST  Pomerantz Law Firm Reminds Shareholders with Losses on their   GlobeNewswire Inc
10:40AM EST  Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Precigen, Inc. f/k/a Intrexon Corporation (NASDAQ: PGEN, XON) between May 10, 2017 and September 25, 2020, inclusive (the Class Period).   GlobeNewswire Inc
04:25AM EST  Precigen, Inc. f/k/a Intrexon Corporation of Class Action Lawsuit and Upcoming Deadline - PGEN   PR Newswire
Dec 2, 2020
11:00AM EST  The Law Offices of Frank R. Cruz reminds investors of the upcomingDecember 4, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Precigen, Inc. (Precigen or the Company) f/k/a Intrexon Corporation (Intrexon) (NASDAQ: PGEN, XON) securities between May 10, 2017 and September 25, 2020,inclusive (the Class Period).   GlobeNewswire Inc
07:35AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod   Benzinga
Dec 1, 2020
11:59PM EST  Intrexon Corporation Investors of Important December 4 Deadline in First Filed Securities Class Action Commenced by the Firm; Encourage Investors with Losses in Excess of $100K to Contact Firm - PGEN, XON   PR Newswire
02:42PM EST  to December 4th Lead Plaintiff Deadline, Encourages Investors with Losses to Contact Its Attorneys   PR Newswire
11:00AM EST  PGEN, MESO & LOOP Upcoming Deadlines: Bronstein, Gewirtz &   GlobeNewswire Inc
Nov 30, 2020
08:00PM EST  DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That   GlobeNewswire Inc
Nov 28, 2020
01:16PM EST  Hagens Berman urges Precigen, Inc. (NASDAQ PGEN) (f/k/a Intrexon) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have sufficient losses to move for lead plaintiff.   GlobeNewswire Inc
Nov 27, 2020
05:00PM EST  Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Precigen, Inc. f/k/a (NASDAQ: PGEN, XON) from May 10, 2017 through September 25, 2020, inclusive (the Class Period). The lawsuit seeks to recover damages for Precigen, Inc. f/k/a Intrexon Corporation investors under the federal securities laws.   GlobeNewswire Inc
10:11AM EST  File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Precigen Inc., f/k/a Intrexon Corporation   PR Newswire
Nov 25, 2020
11:00AM EST  PGEN, MESO & LOOP Class Actions: Bronstein, Gewirtz & Grossman LLC   GlobeNewswire Inc
Nov 24, 2020
06:00PM EST  DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That   GlobeNewswire Inc
11:00AM EST  Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
10:19AM EST  Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Precigen, Inc. f/k/a Intrexon Corporation (NASDAQ: PGEN, XON) between May 10, 2017 and September 25, 2020, inclusive (the Class Period).   GlobeNewswire Inc
09:16AM EST  PGEN CLASS ACTION DEADLINE: Bernstein Liebhard Reminds Investors   GlobeNewswire Inc
Nov 23, 2020
03:12PM EST  Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm. Further details about the cases, including important upcoming deadlines, can be found at the links provided.   GlobeNewswire Inc
12:00PM EST  Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline   GlobeNewswire Inc
Nov 22, 2020
12:24AM EST  Pomerantz Law Firm Reminds Shareholders with Losses on their   GlobeNewswire Inc
Nov 20, 2020
05:42PM EST  ROSEN, RECOGNIZED INVESTOR COUNSEL, Reminds Precigen, Inc. f/k/a   GlobeNewswire Inc
Nov 19, 2020
10:58AM EST  Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Precigen, Inc. f/k/a (NASDAQ: PGEN, XON) from May 10, 2017 through September 25, 2020, inclusive (the Class Period). The lawsuit seeks to recover damages for Precigen, Inc. f/k/a Intrexon Corporation investors under the federal securities laws.   GlobeNewswire Inc
Nov 18, 2020
05:00PM EST  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action   GlobeNewswire Inc
Nov 17, 2020
05:06PM EST  PGEN CLASS ACTION DEADLINE: Bernstein Liebhard Reminds Investors   GlobeNewswire Inc
12:30PM EST  Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
09:39AM EST  Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Precigen, Inc. f/k/a Intrexon Corporation (NASDAQ: PGEN, XON) between May 10, 2017 and September 25, 2020, inclusive (the Class Period).   GlobeNewswire Inc
Nov 16, 2020
09:51PM EST  Pomerantz Law Firm Reminds Shareholders with Losses on their   GlobeNewswire Inc
04:50PM EST  Hagens Berman urges Precigen, Inc. (NASDAQ PGEN) (f/k/a Intrexon) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have valuable claims.   GlobeNewswire Inc
11:30AM EST  The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
08:19AM EST  Precigen Announces Clinical Implementation Of Its UltraPorator System   RTTNews
08:05AM EST  Manufactured Using Proprietary UltraPorator(tm) System in Ongoing PRGN-3005 and PRGN-3006 Phase 1 Clinical Trials   PR Newswire
Nov 13, 2020
12:00PM EST  Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline   GlobeNewswire Inc
Nov 12, 2020
08:05PM EST  Corporation Investors of Important December 4 Deadline in First Filed Securities Class Action Commenced by the Firm; Encourages Investors with Losses in Excess of $100K to Contact Firm - PGEN, XON   PR Newswire
03:22PM EST  Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Precigen, Inc. f/k/a (NASDAQ: PGEN, XON) from May 10, 2017 through September 25, 2020, inclusive (the Class Period). The lawsuit seeks to recover damages for Precigen, Inc. f/k/a Intrexon Corporation investors under the federal securities laws.   GlobeNewswire Inc
09:47AM EST  File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Precigen Inc., f/k/a Intrexon Corporation   PR Newswire
08:00AM EST  Pomerantz Law Firm Reminds Shareholders with Losses on their   GlobeNewswire Inc
Nov 11, 2020
05:00PM EST  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action   GlobeNewswire Inc
01:25PM EST  PGEN CLASS ACTION DEADLINE: Bernstein Liebhard Reminds Investors   GlobeNewswire Inc
11:00AM EST  ACB & PGEN Class Actions: Bronstein, Gewirtz & Grossman LLC   GlobeNewswire Inc
Nov 10, 2020
11:00AM EST  The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
Nov 9, 2020
04:08PM EST  Hagens Berman urges Precigen, Inc. (NASDAQ PGEN) (f/k/a Intrexon) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have valuable claims.   GlobeNewswire Inc
12:00PM EST  Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
08:32AM EST  Precigen: Q3 Earnings Insights   Benzinga
08:15AM EST  Precigen Q3 Net Loss From Cont Ops $29.5 Mln Or $0.18 Per Basic Share   RTTNews
08:12AM EST  Precigen Q3 EPS $(0.18) Misses $(0.14) Estimate, Sales $23.58M Beat $17.70M Estimate   Benzinga
08:06AM EST  Precigen Reports Third Quarter 2020 and Year-to-Date Financial Results   PR Newswire
04:13AM EST  Earnings Scheduled For November 9, 2020   Benzinga
Nov 8, 2020
03:03AM EST  Pomerantz Law Firm Reminds Shareholders with Losses on their   GlobeNewswire Inc
Nov 6, 2020
07:23PM EST  ROSEN, A LEADING LAW FIRM, Reminds Precigen, Inc. f/k/a Intrexon   GlobeNewswire Inc
04:29PM EST  PGEN CLASS ACTION DEADLINE: Bernstein Liebhard Reminds Investors   GlobeNewswire Inc
11:30AM EST  Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline   GlobeNewswire Inc
Nov 4, 2020
11:00AM EST  The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
Nov 3, 2020
12:57PM EST  Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating potential claims involving directors and officers regarding possible breaches of fiduciary duties related to whether insiders caused their companies to make false and/or misleading statements and/or failed to disclose, among other things, that:   GlobeNewswire Inc
Nov 2, 2020
04:06PM EST  Precigen to Announce Third Quarter 2020 Financial Results on November 9th: Will   PR Newswire
01:34PM EST  Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm. Further details about the cases can be found at the links provided.   GlobeNewswire Inc
12:00PM EST  Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
Oct 30, 2020
04:58PM EDT  ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Precigen, Inc.   GlobeNewswire Inc
11:18AM EDT  PGEN CLASS ACTION DEADLINE: Bernstein Liebhard Reminds Investors   GlobeNewswire Inc
Oct 29, 2020
07:05PM EDT  Investors of Important December 4 Deadline in First Filed Securities Class Action Commenced by the Firm; Encourages Investors with Losses in Excess of $100K to Contact Firm - PGEN, XON   PR Newswire
11:17AM EDT  File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Precigen Inc., f/k/a Intrexon Corporation   PR Newswire
Oct 26, 2020
05:35PM EDT  Hagens Berman urges Precigen, Inc. (NASDAQ PGEN) (f/k/a Intrexon) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have valuable claims.   GlobeNewswire Inc
05:03PM EDT  Pomerantz Law Firm Announces the Filing of a Class Action against Precigen,   PR Newswire
04:45PM EDT  ROSEN, A LONGSTANDING AND TRUSTED FIRM, Reminds Precigen, Inc.   GlobeNewswire Inc
12:30PM EDT  Looming Deadline in the Class Action Lawsuit Against Precigen, Inc. f/k/a Intrexon Corporation (PGEN, XON)   PR Newswire
Oct 23, 2020
12:00PM EDT  The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
11:19AM EDT  PGEN CLASS ACTION DEADLINE: Bernstein Liebhard Reminds Investors   GlobeNewswire Inc
Oct 21, 2020
12:01PM EDT  Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class   PR Newswire
Oct 20, 2020
04:00PM EDT  announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of investors that purchased Precigen, Inc.   PR Newswire
09:14AM EDT  Moore Kuehn, PLLC Encourages Investors of PGEN or TCMD to Contact Law Firm   PR Newswire
07:31AM EDT  Precigen Strengthens Focus on Strategic Partnerships and Names Gaurav Vij Head   PR Newswire
Oct 19, 2020
07:15PM EDT  Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm. Further details about the cases can be found at the links provided.   GlobeNewswire Inc
Oct 17, 2020
04:23PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Precigen, Inc (f/k/a Intrexon Corporation) (Precigen or the Company) (NASDAQ:PGEN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Oct 16, 2020
04:33PM EDT  PGEN CLASS ACTION DEADLINE: Bernstein Liebhard Reminds Investors   GlobeNewswire Inc
11:01AM EDT  Action on Behalf of Precigen, Inc. f/k/a Intrexon Corporation (PGEN, XON) Investors   PR Newswire
Oct 15, 2020
06:22PM EDT  File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Precigen Inc., f/k/a Intrexon Corporation   PR Newswire
04:56PM EDT  PRECIGEN, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman   GlobeNewswire Inc
12:18PM EDT  ROSEN, A LEADING AND LONGSTANDING FIRM, Reminds Precigen, Inc.   GlobeNewswire Inc
11:00AM EDT  PGEN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC   GlobeNewswire Inc
08:35AM EDT  Benzinga Pro's Top 4 Stocks To Watch For Thursday, Oct. 15, 2020: CLOU, ZM, PECK, PGEN   Benzinga
07:37AM EDT  Precigen's UltraPorator Receives FDA Clearance For Manufacturing UltraCAR-T Cells In Clinical Trials   RTTNews
07:35AM EDT  Precigen Announces That Its UltraPorator Received FDA Clearance For The Manufacturing Of Its UltraCAR-T Cells In The Clinical Trials   Benzinga
07:31AM EDT  Precigen's UltraPorator(tm) Receives FDA Clearance for Manufacturing   PR Newswire
Oct 14, 2020
08:00PM EDT  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action   GlobeNewswire Inc
Oct 13, 2020
10:01AM EDT  Inc. f/k/a Intrexon Corporation Shareholders of Class Action and Lead Plaintiff Deadline: December 4, 2020   PR Newswire
Oct 12, 2020
05:54PM EDT  Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm. Further details about the cases can be found at the links provided.   GlobeNewswire Inc
04:21PM EDT  Investors of Important Deadline in Securities Class Action First Filed by the Firm; Encourages Investors with Losses in Excess of $100K to Contact the Firm -- PGEN, XON   PR Newswire
Oct 11, 2020
11:35AM EDT  Last Week's Notable Insider Buys: Element Solutions, Selecta Biosciences And More   Benzinga
Oct 10, 2020
03:09AM EDT  Mid-Afternoon Market Update: Nasdaq Rises 1.2%; VivoPower International Shares Spike Higher   Benzinga
03:08AM EDT  Mid-Day Market Update: Gold Gains 2%; ShiftPixy Shares Plunge   Benzinga
Oct 9, 2020
02:30PM EDT  Mid-Afternoon Market Update: Nasdaq Rises 1.2%; VivoPower International Shares Spike Higher   Benzinga
01:29PM EDT  CSX, CN Announce Board Appointments   Benzinga
12:15PM EDT  Mid-Day Market Update: Gold Gains 2%; ShiftPixy Shares Plunge   Benzinga
10:33AM EDT  Why Precigen's Stock Is Trading Higher Today   Benzinga
10:23AM EDT  Shares of Precigen, Inc. (PGEN) jumped about 20% on Friday morning after the company said Merck has increased stake in the company.   RTTNews
08:11AM EDT  Precigen Inc. (PGEN) said Friday that Merck KGaA (MKGAY.PK), through its wholly owned subsidiary, Ares Trading S.A., has elected to voluntarily convert a convertible note with an outstanding principal balance of $25 million to increase its stake in Precigen from about 11.6% to 14.8% of outstanding shares, remaining as Precigen's second largest shareholder.   RTTNews
07:36AM EDT  Precigen Says Merck KGaA Increases Ownership Position Through Exercise Of Convertible Note   RTTNews
07:35AM EDT  Precigen Reports Merck KGaA Raised Stake In Co. Via Voluntary Conversion Of Convertible Note   Benzinga
07:31AM EDT  Precigen Announces Merck KGaA, Darmstadt, Germany Increases Ownership Position   PR Newswire
Oct 8, 2020
08:00PM EDT  Investors with a $100,000 or more in losses are encouraged to contact the firm.   GlobeNewswire Inc
07:34PM EDT  ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, First Files Securities Class Action   PR Newswire
06:17PM EDT  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of   PR Newswire
09:00AM EDT  CSX Corp. (NASDAQ: CSX) today announced that Lt. General (Ret.) Thomas Bostick has been appointed to the company's board of directors, effective immediately.   GlobeNewswire Inc
Oct 7, 2020
06:35PM EDT  PGEN INVESTOR ALERT: Bernstein Liebhard Announces that a Securities Class Action Lawsuit Has Been Filed Against Precigen Inc., f/k/a Intrexon Corporation   Business Wire
06:19PM EDT  Hagens Berman urges Precigen, Inc. (NASDAQ PGEN) (f/k/a Intrexon) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have valuable claims.   GlobeNewswire Inc
02:30PM EDT  PRECIGEN ALERT: Bragar Eagel & Squire, P.C. Announces That a Class   GlobeNewswire Inc
10:07AM EDT  Gainey McKenna & Egleston Announces A ClassAction   GlobeNewswire Inc
Oct 6, 2020
04:13PM EDT  HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Precigen, Inc. (PGEN),   PR Newswire
09:47AM EDT  PGEN LOSSES ALERT: Bernstein Liebhard is Investigating Precigen Inc., f/k/a Intrexon Corporation For Violations of the Securities Laws   Business Wire
Oct 5, 2020
11:00PM EDT  ROSEN, A TOP RANKED LAW FIRM, First Files Securities Class Action   GlobeNewswire Inc
08:00PM EDT  Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Precigen, Inc. (NASDAQ: PGEN) f/k/a Intrexon Corporation on behalf of long-term stockholders. Our investigation concerns whether the board of directors of Precigen have breached their fiduciary duties to the company.   GlobeNewswire Inc
05:49PM EDT  Hagens Berman urges Precigen, Inc. (NASDAQ PGEN) (f/k/a Intrexon) investors with significant losses to submit your losses now.   GlobeNewswire Inc
09:47AM EDT  PGEN INVESTIGATION ALERT: Bernstein Liebhard Is Investigating Precigen Inc., f/k/a Intrexon Corporation for Violations of the Securities Laws   Business Wire
Oct 2, 2020
09:12PM EDT  f/k/a Intrexon Corp. (XON) Investors with Losses to Contact Its Attorneys, SEC Finds Company Violated Securities Laws   PR Newswire
Sep 8, 2020
07:31AM EDT  Precigen to Present at H.C. Wainwright 22nd Annual Global Investment Conference   PR Newswire
Aug 19, 2020
02:48PM EDT  Why Precigen's Stock Is Trading Higher Today   Benzinga
Aug 17, 2020
07:34AM EDT  Precigen:First Patient Dosed In Phase I/II Study Of PRGN-2009 AdenoVerse Immunotherapy To Treat HPV-associated Cancers   RTTNews
07:33AM EDT  Precigen Announces First Patient Dosed in Phase I/II Study of First-in-Class PRGN-2009 AdenoVerse Immunotherapy to Treat HPV-associated Cancers   Benzinga
07:30AM EDT  Precigen Announces First Patient Dosed in Phase I/II Study of First-in-Class   PR Newswire
Aug 10, 2020
04:13PM EDT  Precigen Q2 EPS $(0.26) Misses $(0.13) Estimate, Sales $30.40M Beat $13.76M Estimate   Benzinga
04:10PM EDT  Precigen Reports Second Quarter and First Half 2020 Financial Results   PR Newswire
07:57AM EDT  Precigen ActoBio Announces Topline Results From Phase 1b Study Of AG019 ActoBiotics; Study Met Primary Endpoint Demonstrating Safety And Tolerability   Benzinga
07:42AM EDT  Precigen ActoBio Announces Positive Topline Results From Phase 1b Study Of AG019 ActoBiotics   RTTNews
07:42AM EDT  AG019 ActoBiotics(tm), A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes   PR Newswire
04:10AM EDT  Earnings Scheduled For August 10, 2020   Benzinga
Aug 6, 2020
07:59AM EDT  Precigen Triple-Gene Provides Six-Month Follow-Up Data From Phase I Study Of INXN-4001, A Multigenic Investigational Therapeutic Candidate For Heart Failure   Benzinga
07:31AM EDT  INXN-4001, a Multigenic Investigational Therapeutic Candidate for Heart Failure   PR Newswire
Aug 3, 2020
07:31AM EDT  Precigen to Announce Second Quarter and First Half 2020 Financial Results on   PR Newswire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC